论文信息 - Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. - 字舞流文

Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.

Tom R. Gaunt | O. Franco | A. Hofman | A. Uitterlinden | M. Tobin | D. Lawlor | Mingyao Li | S. Yusuf | J. Boer | J. Mega | B. Horne | N. Samani | A. Hall | P. Braund | M. Farrall | J. Carlquist | Jeffrey L. Anderson | H. Brenner | S. Humphries | A. Hingorani | M. Sabatine | A. Dehghan | D. Rader | M. Guardiola | P. Whincup | N. Sattar | M. Sandhu | P. Harst | D. Rothenbacher | C. Nelson | A. Hamsten | A. Franco‐Cereceda | P. Eriksson | H. Nathoe | M. Scholz | D. Morrow | A. Nicolaides | J. Jukema | J. Verschuren | J. Pitha | W. Spiering | W. Koenig | H. Watkins | I. Day | S. Mehta | A. Goel | L. Folkersen | F. Veglia | M. Trip | J. Price | K. Khaw | D. Baldassarre | E. Tremoli | M. Kumari | M. Kivimaki | G. Navis | G. Paré | J. Casas | K. Fox | S. Boekholdt | I. M. Leach | S. Trompet | I. Ford | R. Gansevoort | F. Asselbergs | U. Faire | M. Holmes | R. Morris | L. Holdt | D. Teupser | N. Onland-Moret | J. Cooper | J. Thiery | T. Palmer | B. Keating | N. Danchin | O. Klungel | T. Simon | T. Hooft | K. Kuchenbaecker | P. Knijff | M. Hofker | M. Leusink | A. Tedgui | J. Palmen | F. Beutner | A. Panayiotou | J. Hubacek | V. Adámková | Z. Mallat | S. Tsimikas | J. Stephens | A. Olsson | P. Doevendans | M. Cramer | K. Carruthers | G. Schwartz | E. V. Iperen | D. Swerdlow | J. C. Witteman | K. Brunisholz | G. Hovingh | D. Dallmeier | C. L. Haase | H. Exeter | R. Poledne | L. Breitling | S. Kotti | E. Staines-Urias | F. van | Jaqueline C. M. Witteman

[1] R. Rosenson,et al. Phospholipase A2 enzymes and the risk of atherosclerosis. , 2012, European heart journal.

[2] A. Dominiczak,et al. Genetic basis of blood pressure and hypertension. , 2012, Trends in genetics : TIG.

[3] A. Tedgui,et al. Phospholipase A2 Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes , 2012, Circulation.

[4] J. Kastelein,et al. Inhibition of Secretory Phospholipase A2 in Patients with Acute Coronary Syndromes: Rationale and Design of the Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks (VISTA-16) Trial , 2012, Cardiovascular Drugs and Therapy.

[5] S. Solomon,et al. Prognostic utility of secretory phospholipase A(2) in patients with stable coronary artery disease. , 2011, Clinical chemistry.

[6] Christopher D. Brown,et al. Identification, Replication, and Functional Fine-Mapping of Expression Quantitative Trait Loci in Primary Human Liver Tissue , 2011, PLoS genetics.

[7] R. Rosenson,et al. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease. , 2011, European heart journal.

[8] W. Cantor,et al. The sPLA2 Inhibition to Decrease Enzyme Release After Percutaneous Coronary Intervention (SPIDER-PCI) Trial , 2010, Circulation.

[9] G. Lambeau,et al. Lipoprotein-Associated and Secreted Phospholipases A2 in Cardiovascular Disease: Roles as Biological Effectors and Biomarkers , 2010, Circulation.

[10] D. Waters,et al. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients. , 2010, Journal of the American College of Cardiology.

[11] Tanya M. Teslovich,et al. Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[12] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2010, International journal of surgery.

[13] D. Waters,et al. Effects of 1-H-indole-3-glyoxamide (A-002) on concentration of secretory phospholipase A2 (PLASMA study): a phase II double-blind, randomised, placebo-controlled trial , 2009, The Lancet.

[14] Heather L Rick,et al. Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE−/− Mice , 2009, Journal of cardiovascular pharmacology.

[15] George Davey Smith,et al. Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology , 2008, Statistics in medicine.

[16] D. Lawlor,et al. Re: Estimation of bias in nongenetic observational studies using "Mendelian triangulation" by Bautista et al. , 2007, Annals of epidemiology.

[17] R. Luben,et al. Circulating Secretory Phospholipase A2 Activity and Risk of Incident Coronary Events in Healthy Men and Women: The EPIC-NORFOLK Study , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[18] S. Humphries,et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2IIa: results from the UDACS study. , 2006, Human molecular genetics.

[19] B. Asselain,et al. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes. , 2005, Journal of the American College of Cardiology.

[20] D. Praticò,et al. Macrophage-specific expression of group IIA sPLA2 results in accelerated atherogenesis by increasing oxidative stress Published, JLR Papers in Press, May 16, 2005. DOI 10.1194/jlr.M400469-JLR200 , 2005, Journal of Lipid Research.

[21] N. Day,et al. Serum Levels of Type II Secretory Phospholipase A2 and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women: The EPIC-Norfolk Prospective Population Study , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[22] Keith R Abrams,et al. An integrated approach to the meta-analysis of genetic association studies using Mendelian randomization. , 2004, American journal of epidemiology.

[23] N. Roehm,et al. Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI. , 1999, The Journal of pharmacology and experimental therapeutics.